We are live on ! Find out more
SLN

Silence Therapeutics
SLN

2 hedge funds and large institutions have $8.13M invested in Silence Therapeutics in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1.81% more ownership

Funds ownership: 0% → 1.81% (+1.8%)

Holders
2
Holders Change
+2
Holders Change %
–
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LOAMU
Lombard Odier Asset Management (USA)
New York
+$9.98M
2
Morgan Stanley
Morgan Stanley
New York
+$37K

Top Sellers

No sellers this quarter

SLN Hedge Fund Activity: Q3 2020 in Review

2 of the 4,971 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q3 2020, worth a combined $8.13M.

Buyers outnumbered sellers: 2 funds opened new SLN positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Lombard Odier Asset Management (USA), opening a new position worth an estimated $9.98M.

  • 2 institutional investors held Silence Therapeutics (SLN) as of Q3 2020, up from 0 in Q2 2020.
  • Funds reported $8.13M of Silence Therapeutics stock for Q3 2020.
  • 2 funds opened new Silence Therapeutics positions in Q3 2020 and 0 closed out, a net change of +2 holders.
  • The largest Silence Therapeutics buyer in Q3 2020 was Lombard Odier Asset Management (USA), an estimated $9.98M added.

Based on aggregated 13F filings for Q3 2020.